New family of protein-based antagonists shows promise against leukemia

In a significant advancement for cancer research, a team of scientists from Max Planck Institute for Biology Tübingen, University Hospital Tübingen, and Osnabrück University successfully designed a new family of protein-based antagonists that selectively block the G-CSFR receptor, which is linked to the emergence of several blood cancers, including acute myeloid leukemia.